Very interesting article about KRAS: https://www.nature.com/articles/d41586-022-03392-2Its the significance of the stats that is intriguing in this write-up and perhaps sheds light on why PTX100 could have so much potential... not just for PTCL and CTCL sufferers but a far broader range of prevalent cancers. In fact, the patients in the previous basket trial (including some with solid tumors) derived stable disease albeit they did not live beyond the timespan the commercial drug Folotyn offers. The fact that the trial demonstrated that the various cancer types stabilised, means the mechanism of action works.

PTX100 is applicable across all RAS pathways not just KRAS which is significant in itself and is believed to be the only RhoA inhibitor in the world in clinical development. And, its in our favour that it seems that the clinical responses to a KRAS drug is really causing some excitement. So, perhaps its no wonder our presentation at the European conference seems to be focused on PTX100. Our targeted drug is the only one in

• NEWS FEATURE
• 25 October 2022

Cancer drugs are closing in on some of the deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

Only 28% of the participants treated with sotorasib responded to it. That’s roughly twice the number who responded to the standard chemotherapy, but a sign nonetheless that most people who have KRAS-positive lung cancers will not be helped by the new drug.

Even so, the pace of KRAS research and the pursuit of KRAS-targeting drugs has never been so energized, says cancer biologist Channing Der at the University of North Carolina in Chapel Hill. The first glimpse of success has shown that it is possible todrug the ‘undruggable’ KRAS, and now researchers in academia and industry are developing ways to improve their approach. “I have never seen this level of excitement and buzz in the entire history of the field,” he says. “The level now is insane.”

PTX100 has such broad potential in this space, that the stockmarket pundits are seemingly overlooking. The price action we are seeing could well be a group of LTH who are well-versed in the ignorance of the market taking advantage of the general mismatched sentiment to move the SP and load up on this speculative but potentially highly rewarding biotech gem. I'm mindful too that they hold a swag of oppies which I'm hoping won't spell my demise! C'mon, PTX, land some partnerships, pleeeaaase!!!